drugset / Trial / NCT01947933
A Safety Study of Mirikizumab (LY3074828)
RandomizedParallel-groupDouble-blindBasic science
Summary
The main purpose of this study is to evaluate the safety of the study drug known as mirikizumab. The study will investigate how the body processes the study drug and how the drug affects the body. The study will last about 3 months for each participant.
Timeline
- Start
- 2013-10
- Primary completion
- 2015-02
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirikizumab | Monoclonal antibody | 5 mg | Intravenous |
| Subject | Mirikizumab | Monoclonal antibody | 20 mg | Intravenous |
| Subject | Mirikizumab | Monoclonal antibody | 60 mg | Intravenous |
| Subject | Mirikizumab | Monoclonal antibody | 120 mg | Intravenous |
| Subject | Mirikizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Mirikizumab | Monoclonal antibody | 350 mg | Intravenous |
| Subject | Mirikizumab | Monoclonal antibody | 600 mg | Intravenous |